Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Autoimmunity Highlights
Published in: Autoimmunity Highlights 1/2020

Open Access 01-12-2020 | Review

Twenty years of research on the DFS70/LEDGF autoantibody-autoantigen system: many lessons learned but still many questions

Authors: Greisha L. Ortiz-Hernandez, Evelyn S. Sanchez-Hernandez, Carlos A. Casiano

Published in: Autoimmunity Highlights | Issue 1/2020

Login to get access

Abstract

The discovery and initial characterization 20 years ago of antinuclear autoantibodies (ANAs) presenting a dense fine speckled (DFS) nuclear pattern with strong staining of mitotic chromosomes, detected by indirect immunofluorescence assay in HEp-2 cells (HEp-2 IIFA test), has transformed our view on ANAs. Traditionally, ANAs have been considered as reporters of abnormal immunological events associated with the onset and progression of systemic autoimmune rheumatic diseases (SARD), also called ANA-associated rheumatic diseases (AARD), as well as clinical biomarkers for the differential diagnosis of these diseases. However, based on our current knowledge, it is not apparent that autoantibodies presenting the DFS IIF pattern fall into these categories. These antibodies invariably target a chromatin-associated protein designated as dense fine speckled protein of 70 kD (DFS70), also known as lens epithelium-derived growth factor protein of 75 kD (LEDGF/p75) and PC4 and SFRS1 Interacting protein 1 (PSIP1). This multi-functional protein, hereafter referred to as DFS70/LEDGF, plays important roles in the formation of transcription complexes in active chromatin, transcriptional activation of specific genes, regulation of mRNA splicing, DNA repair, and cellular survival against stress. Due to its multiple functions, it has emerged as a key protein contributing to several human pathologies, including acquired immunodeficiency syndrome (AIDS), leukemia, cancer, ocular diseases, and Rett syndrome. Unlike other ANAs, “monospecific” anti-DFS70/LEDGF autoantibodies (only detectable ANA in serum) are not associated with SARD and have been detected in healthy individuals and some patients with non-SARD inflammatory conditions. These observations have led to the hypotheses that these antibodies could be considered as negative biomarkers of SARD and might even play a protective or beneficial role. In spite of 20 years of research on this autoantibody-autoantigen system, its biological and clinical significance still remains enigmatic. Here we review the current state of knowledge of this system, focusing on the lessons learned and posing emerging questions that await further scrutiny as we continue our quest to unravel its significance and potential clinical and therapeutic utility.
Literature
1.
Tan EM. Autoantibodies and autoimmunity: a three-decade perspective. A tribute to Henry G. Kunkel. Ann N Y Acad Sci. 1997;815:1–14.PubMedCrossRef
2.
3.
Damoiseaux J, Andrade LEC, Carballo OG, et al. Clinical relevance of HEp-2 indirect immunofluorescent patterns: the international consensus on ANA patterns (ICAP) perspective. Ann Rheum Dis. 2019;78:879–89.PubMedCrossRef
4.
Ganapathy V, Casiano CA. Autoimmunity to the nuclear autoantigen DFS70 (LEDGF): what exactly are the autoantibodies trying to tell us? Arthritis Rheum. 2004;50:684–8.PubMedCrossRef
5.
Ochs RL, Stein TW Jr, Peebles CL, et al. Autoantibodies in interstitial cystitis. J Urol. 1994;151:587–92.PubMedCrossRef
6.
Ochs RL, Muro Y, Si Y, et al. Autoantibodies to DFS 70 kd/transcription coactivator p75 in atopic dermatitis and other conditions. J Allergy Clin Immunol. 2000;105:1211–20.PubMedCrossRef
7.
Ge H, Si Y, Roeder RG. Isolation of cDNAs encoding novel transcription coactivators p52 and p75 reveals an alternate regulatory mechanism of transcriptional activation. EMBO J. 1998;17:6723–9.PubMedPubMedCentralCrossRef
8.
Singh DP, Ohguro N, Chylack LT, Shinohara T. Lens epithelium-derived growth factor: increased resistance to thermal and oxidative stresses. Invest Ophthalmol Vis Sci. 1999;40:1444–51.PubMed
9.
Singh DP, Ohguro N, Kikuchi T, et al. Lens epithelium-derived growth factor: effects on growth and survival of lens epithelial cells, keratinocytes, and fibroblasts. Biochem Biophys Res Commun. 2000;267:373–81.PubMedCrossRef
10.
Shinohara T, Singh DP, Chylack LT. Review: age-related cataract: immunity and lens epithelium-derived growth factor (LEDGF). J Ocul Pharmacol Ther. 2000;16:181–91.PubMedCrossRef
11.
Nakamura M, Singh DP, Kubo E, et al. LEDGF: survival of embryonic chick retinal photoreceptor cells. Invest Ophthalmol Vis Sci. 2000;41:1168–75.PubMed
12.
Sharma P, Singh DP, Fatma LT, et al. Activation of LEDGF gene by thermal- and oxidative-stresses. Biochem Biophys Res Commun. 2000;276:1320–4.PubMedCrossRef
13.
Fatma N, Singh DP, Shinohara T, Chrylack LT Jr. Transcriptional regulation of the AOP2 gene, a thiol-specific antioxidant, by LEDGF to protect cells from oxidative stress. J Biol Chem. 2001;276:48899–907.PubMedCrossRef
14.
Nishizawa Y, Usukura J, Singh DP, et al. Spatial and temporal dynamics of two alternatively spliced regulatory factors, lens epithelium-derived growth factor (ledgf/p75) and p52, in the nucleus. Cell Tissue Res. 2001;305:107–14.PubMedCrossRef
15.
Singh DP, Fatma N, Kimura A, et al. LEDGF binds to heat shock and stress-related element to activate the expression of stress-related genes. Biochem Biophys Res Commun. 2001;283:943–55.PubMedCrossRef
16.
Shinohara T, Singh DP, Fatma N. LEDGF, a survival factor, activates stress-related genes. Prog Retin Ocular Res. 2002;21:341–58.CrossRef
17.
Matsui H, Lin LR, Singh DP, et al. Lens epithelium-derived growth factor: increased survival and decreased DNA breakage of human RPE cells induced by oxidative stress. Invest Ophthalmol Vis Sci. 2002;42:2935–41.
18.
Kubo E, Fatma N, Sharma P, et al. Transactivation of involucrin, a marker of differentiation in keratinocytes, by lens epithelium-derived growth factor (LEDGF). J Mol Biol. 2002;320:1053–63.PubMedCrossRef
19.
Inomata Y, Hirata A, Koga T, et al. Lens epithelium-derived growth factor: neuroprotection on rat retinal damage induced by N-methyl-d-aspartate. Brain Res. 2003;991:163–70.PubMedCrossRef
20.
Fatma N, Kubo E, Chylack LT, et al. LEDGF regulation of alcohol and aldehyde dehydrogenases in lens epithelial cells: stimulation of retinoic acid production and protection from ethanol toxicity. Am J Physiol Cell Physiol. 2004;287:C508–16.PubMedCrossRef
21.
Singh DP, Kimura A, Chylack LT, Shinohara T. Lens epithelium-derived growth factor (LEDGF/p75) and p52 are derived from a single gene by alternative splicing. Gene. 2000;242:265–73.PubMedCrossRef
22.
Takamura Y, Fatma N, Kubo E, Singh DP. Regulation of heavy subunit chain of gamma-glutamylcysteine synthetase by tumor necrosis factor-alpha in lens epithelial cells: role of LEDGF/p75. Am J Physiol Cell Physiol. 2006;290:C554–66.PubMedCrossRef
23.
Shin JH, Piao CS, Lim CM, Lee JK. LEDGF binding to stress response element increases alphaB-crystallin expression in astrocytes with oxidative stress. Neurosci Lett. 2008;435:131–6.PubMedCrossRef
24.
Cohen B, Addadi Y, Sapoznik S, et al. Transcriptional regulation of vascular endothelial growth factor C by oxidative and thermal stress is mediated by lens epithelium-derived growth factor/p75. Neoplasia. 2009;11:921–33.PubMedPubMedCentralCrossRef
25.
Sapoznik S, Cohen B, Tzuman Y, et al. Gonadotropin-regulated lymphangiogenesis in ovarian cancer is mediated by LEDGF-induced expression of VEGF-C. Cancer Res. 2009;69:9306–14.PubMedPubMedCentralCrossRef
26.
Basu A, Drame A, Muñoz R, et al. Pathway specific gene expression profiling reveals oxidative stress genes potentially regulated by transcription co-activator LEDGF/p75 in PCa cells. Prostate. 2012;72:597–611.PubMedCrossRef
27.
Bhargavan B, Fatma N, Chhunchha B, et al. LEDGF gene silencing impairs the tumorigenicity of PCa DU145 cells by abating the expression of Hsp27 and activation of the Akt/ERK signaling pathway. Cell Death Dis. 2012;3:e316.PubMedPubMedCentralCrossRef
28.
Takeichi T, Sugiura K, Muro Y, et al. Overexpression of LEDGF/DFS70 induces IL-6 via p38 activation in HaCaT cells, similar to that seen in the psoriatic condition. J Invest Dermatol. 2010;130:2760–7.PubMedCrossRef
29.
Takeichi T, Sugiura K, Muro Y, et al. LEDGF/DFS70 activates the MK2/IL6/STAT3 pathway in HaCaT. J Dermatol Sci. 2011;63:203–5.PubMedCrossRef
30.
Leoh LS, van Heertum B, De Rijck J, et al. The stress oncoprotein LEDGF/p75 interacts with the methyl CpG binding protein MeCP2 and influences its transcriptional activity. Mol Cancer Res. 2012;10:378–91.PubMedPubMedCentralCrossRef
31.
Basu A, Cajigas-Du Ross C, Rios-Colon L, et al. LEDGF/p75 overexpression attenuates oxidative stress-induced necrosis and upregulates ERp57/PDIA3/GRp58 in prostate cancer. PLoS ONE. 2016;11:e0146549.PubMedPubMedCentralCrossRef
32.
Kubo E, Shibata T, Singh DP, Sasaki H. Roles of TGF beta and FGF signals in the lens: tropomyosisn regulation for posterior capsule opacity. Int J Mol Sci. 2018;19(10):3093.PubMedCentralCrossRef
33.
Dietz F, Franken S, Yoshida K, et al. The family of hepatoma-growth factor proteins: characterization of a new member HRP-4 and classification of its subfamilies. Biochem J. 2002;366:491–500.PubMedPubMedCentralCrossRef
34.
Bao C, Wang J, Ma W, et al. HDGF: a novel jack-of-all-trades in cancer. Future Oncol. 2014;10:2675–85.PubMedCrossRef
35.
Shetty A, Dasari S, Banerjee S, et al. Hepatoma-derived growth factor: a survival-related protein in prostate oncogenesis and a potential target for vitamin K2. Urol Oncol. 2016;34:483.PubMedPubMedCentralCrossRef
36.
Wu X, Daniels T, Molinaro C, et al. Caspase cleavage of the nuclear autoantigen LEDGF/p75 abrogates its pro-survival function: implications for autoimmunity in atopic disorders. Cell Death Differ. 2002;9:915–25.PubMedCrossRef
37.
Turlure F, Maertens G, Rahman S, et al. A tripartite DNA-binding element, comprised of the nuclear localization signal and two AT-hook motifs, mediates the association of LEDGF/p75 with chromatin in vivo. Nucleic Acids Res. 2006;34:1653–75.PubMedPubMedCentralCrossRef
38.
Llano M, Vanegas M, Hutchins N, et al. Identification and characterization of the chromatin-binding domains of the HIV-1 integrase interactor LEDGF/p75. J Mol Biol. 2006;360:760–73.PubMedCrossRef
39.
Wu X, Molinaro C, Johnson N, Casiano CA. Secondary necrosis is a source of proteolytically modified forms of specific intracellular autoantigens: implications for autoimmunity. Arthritis Rheum. 2001;44:2642–52.PubMedCrossRef
40.
Brown-Bryan TA, Leoh LS, Ganapathy V, et al. Alternative splicing and caspase-mediated cleavage generate antagonistic variants of the stress oncoprotein LEDGF/p75. Mol Cancer Res. 2008;6:1293–307.PubMedPubMedCentralCrossRef
41.
Singh DP, Kubo E, Takamura Y, et al. DNA binding domains and nuclear localization signal of LEDGF: contribution of two helix-turn-helix (HTH)-like domains and a stretch of 58 amino acids of the N-terminal to the trans-activation potential of LEDGF. J Mol Biol. 2006;355:379–94.PubMedCrossRef
42.
Debyser Z, Christ F, De Rijck J, Gijsbers R. Host factors for retroviral integration site selection. Trends Biochem Sci. 2015;40:108–16.PubMedCrossRef
43.
44.
Llano M, Morrison J, Poeschla EM. Virological and cellular roles of the transcriptional coactivator LEDGF/p75. Curr Top Microbiol Immunol. 2009;339:125–46.PubMedPubMedCentral
45.
Blokken J, De Rijck J, Christ F, Debyser Z. Protein-protein and protein-chromatin interactions of LEDGF/p75 as novel drug targets. Drug Discov Today Technol. 2017;24:25–31.PubMedCrossRef
46.
Tesina P, Čermáková K, Hořejší M, et al. Multiple cellular proteins interact with LEDGF/p75 through a conserved unstructured consensus motif. Nat Commun. 2015;6:7968.PubMedCrossRef
47.
Wang H, Farnung L, Dienemann C, Cramer P. Structure of H3K36-methylated nucleosome-PWWP complex reveals multivalent cross-gyre binding. Nat Struct Mol Biol. 2020;27:8–13.PubMedCrossRef
48.
LeRoy G, Oksuz O, Descostes N, et al. LEDGF and HDGF2 relieve the nucleosome-induced barrier to transcription in differentiated cells. Sci Adv. 2019;5:eaay3068.PubMedPubMedCentralCrossRef
49.
Cherepanov P, Devroe E, Silver PA, Engelman A. Identification of an evolutionarily conserved domain in human lens epithelium-derived growth factor/transcriptional co-activator p75 (LEDGF/p75) that binds HIV-1 integrase. J Biol Chem. 2004;279:48883–92.PubMedCrossRef
50.
Vandekerckhove L, Christ F, Van Maele B, et al. Transient and stable knockdown of the integrase cofactor LEDGF/p75 reveals its role in the replication cycle of human immunodeficiency virus. J Virol. 2006;80:1886–96.PubMedPubMedCentralCrossRef
51.
Lampi Y, Van Looveren D, Vranckx LS, et al. Targeted editing of the PSIP1 gene encoding LEDGF/p75 protects cells against HIV infection. Sci Rep. 2019;9:2389.PubMedPubMedCentralCrossRef
52.
Fadel HJ, Morrison JH, Saenz DT, et al. TALEN knockout of the PSIP1 gene in human cells: analyses of HIV-1 replication and allosteric integrase inhibitor mechanism. J Virol. 2014;88:9704–17.PubMedPubMedCentralCrossRef
53.
Schrijvers R, De Rijck J, Demeulemeester J, et al. LEDGF/p75-independent HIV-1 replication demonstrates a role for HRP-2 and remains sensitive to inhibition by LEDGINS. PLoS Pathog. 2012;8:e1002558.PubMedPubMedCentralCrossRef
54.
Wang H, Jurado KA, Wu X, et al. HRP2 determines the efficiency and specificity of HIV-1 integration in LEDGF/p75 knockout cells but does not contribute to the antiviral activity of a potent LEDGF/p75-binding site integrase inhibitor. Nucleic Acids Res. 2012;40:11518–30.PubMedPubMedCentralCrossRef
55.
Daugaard M, Baude A, Fugger K, et al. LEDGF (p75) promotes DNA-end resection and homologous recombination. Nat Struct Mol Biol. 2012;19:803–10.PubMedCrossRef
56.
Morchikh M, Naughtin M, Di Nunzio F, et al. TOX4 and NOVA1 proteins are partners of the LEDGF PWWP domain and affect HIV-1 replication. PLoS ONE. 2013;8:e81217.PubMedPubMedCentralCrossRef
57.
Singh PK, Plumb MR, Ferris AL, et al. LEDGF/p75 interacts with mRNA splicing factors and targets HIV-1 integration to highly spliced genes. Genes Dev. 2015;29:2287–97.PubMedPubMedCentralCrossRef
58.
59.
60.
61.
Sharma S, Čermáková K, De Rijck J, et al. Affinity switching of the LEDGF/p75 IBD interactome is governed by kinase-dependent phosphorylation. Proc Natl Acad Sci USA. 2018;115:E7053–62.PubMedCrossRefPubMedCentral
62.
Hannon C, Cruz-Migoni A, Platonova O, et al. Cloning, purification and structure determination of the HIV integrase-binding domain of lens epithelium-derived growth factor. Acta Crystallogr F Struct Biol Commun. 2018;74:143–9.PubMedPubMedCentralCrossRef
63.
Frege T, Uversky VN. Intrinsically disordered proteins in the nucleus of human cells. Biochem Biophys Rep. 2015;1:33–51.PubMedPubMedCentral
64.
Liu J, Perumal NB, Oldfield CJ, et al. Intrinsic disorder in transcription factors. Biochemistry. 2006;45:6873–88.PubMedCrossRef
65.
Wright PE, Dyson HJ. Intrinsically unstructured proteins: re-assessing the protein structure-function paradigm. J Mol Biol. 1999;293:321–31.PubMedCrossRef
66.
67.
68.
Carl PL, Temple BR, Cohen PL. Most nuclear systemic autoantigens are extremely disordered proteins: implications for the etiology of systemic autoimmunity. Arthritis Res Ther. 2005;7:R1360–74.PubMedPubMedCentralCrossRef
69.
Ogawa Y, Sugiura K, Watanabe A, et al. Autoantigenicity of DFS70 is restricted to the conformational epitope of C-terminal alpha-helical domain. J Autoimmun. 2004;23:221–31.PubMedCrossRef
70.
Ochs RL, Mahler M, Basu A, et al. The significance of autoantibodies to DFS70/LEDGF in health and disease: integrating basic science with clinical understanding. Clin Exp Med. 2016;16:273–93.PubMedCrossRef
71.
Ahuja HG, Hong J, Aplan PD, et al. t(9;11)(p22;p15) in acute myeloid leukemia results in a fusion between NUP98 and the gene encoding transcriptional coactivators p52 and p75-lens epithelium-derived growth factor (LEDGF). Cancer Res. 2000;60:6227–9.PubMed
72.
Grand FH, Koduru P, Cross NC, Allen SL. NUP98-LEDGF fusion and t(9;11) in transformed chronic myeloid leukemia. Leuk Res. 2005;29:1469–72.PubMedCrossRef
73.
Morerio C, Acquila M, Rosanda C, et al. t(9;11)(p22;p15) with NUP98-LEDGF fusion gene in pediatric acute myeloid leukemia. Leuk Res. 2005;29:467–70.PubMedCrossRef
74.
Huang TS, Myklebust LM, Kjarland E, et al. LEDGF/p75 has increased expression in blasts from chemotherapy-resistant human acute myelogenic leukemia patients and protects leukemia cells from apoptosis in vitro. Mol Cancer. 2007;6:31.PubMedPubMedCentralCrossRef
75.
76.
Ashkar SE, Schwaller J, Pieters T, et al. LEDGF/p75 is dispensable for hematopoiesis but essential for MLL-rearranged leukemogenesis. Blood. 2018;131:95–107.PubMedPubMedCentral
77.
Méreau H, De Rijck J, Cermáková K, et al. Impairing MLL-fusion gene-mediated transformation by dissecting critical interactions with the lens epithelium-derived growth factor (LEDGF/p75). Leukemia. 2013;27:1245–53.PubMedCrossRef
78.
Cermakova K, Weydert C, Christ F, et al. Lessons learned: HIV points the way towards precision treatment of mixed-lineage leukemia. Trends Pharmacol Sci. 2016;37:660–71.PubMedCrossRef
79.
Daniels T, Zhang J, Gutierrez I, et al. Antinuclear autoantibodies in PCa: immunity to LEDGF/p75, a survival protein highly expressed in prostate tumors and cleaved during apoptosis. Prostate. 2005;62:14–26.PubMedCrossRef
80.
Basu A, Rojas H, Banerjee H, et al. Expression of the stress response oncoprotein LEDGF/p75 in human cancer: a study of 21 tumor types. PLoS ONE. 2012;7:e30132.PubMedPubMedCentralCrossRef
81.
Mediavilla-Varela M, Pacheco FJ, Almaguel F, et al. Docetaxel-induced PCa cell death involves concomitant activation of caspase and lysosomal pathways and is attenuated by LEDGF/p75. Mol Cancer. 2009;8:68.PubMedPubMedCentralCrossRef
82.
Rios-Colon L, Cajigas-Du Ross C, Basu A, et al. Targeting the stress oncoprotein LEDGF/p75 to sensitize chemoresistant prostate cancer cells to taxanes. Oncotarget. 2017;8:24915–31.PubMedPubMedCentralCrossRef
83.
Cajigas-Du Ross CK, Martinez SR, Woods-Burnham L, et al. RNA sequencing reveals upregulation of a transcriptomic program associated with stemness in metastatic prostate cancer cells selected for taxane resistance. Oncotarget. 2018;9:30363–84.PubMedPubMedCentral
84.
Daugaard M, Kirkegaard-Sorensen T, Ostenfeld MS, et al. Lens epithelium-derived growth factor is an Hsp70-2 regulated guardian of lysosomal stability in human cancer. Cancer Res. 2007;67:2559–67.PubMedCrossRef
85.
Leitz J, Reuschenbach M, Lohrey C, et al. Oncogenic human papillomaviruses activate the tumor-associated lens epithelial-derived growth factor (LEDGF) gene. PLoS Pathog. 2014;10:e1003957.PubMedPubMedCentralCrossRef
86.
Singh DK, Gholamalamdari O, Jadaliha M, et al. PSIP1/p75 promotes tumorigenicity in breast cancer cells by promoting the transcription of cell cycle genes. Carcinogenesis. 2017;38:966–75.PubMedPubMedCentralCrossRef
87.
Yin XH, Wang ZQ, Guo QH, et al. Overexpressed LEDGF is a novel biomarker of poor prognosis in patients with cervical cancer. Eur J Gynaecol Oncol. 2017;38:245–50.PubMed
88.
Chan TS, Hawkins C, Krieger JR, et al. JPO2/CDCA7L and LEDGF/p75 are novel mediators of PI3K/AKT signaling and aggressive phenotypes in medulloblastoma. Cancer Res. 2016;76:2802–12.PubMedCrossRef
89.
Rammer P, Groth-Pedersen L, Kirkegaard T, et al. BAMLET activates a lysosomal cell death program in cancer cells. Mol Cancer Ther. 2010;9:24–32.PubMedCrossRef
90.
Sutherland HG, Newton K, Brownstein DG, et al. Disruption of Ledgf/Psip1 results in perinatal mortality and homeotic skeletal transformations. Mol Cell Biol. 2006;26:7201–10.PubMedPubMedCentralCrossRef
91.
Woods-Burnham L, Cajigas-Du Ross CK, Love A, et al. Glucocorticoids induce stress oncoproteins associated with therapy-resistance in African American and European American prostate cancer cells. Sci Rep. 2018;8:15063.PubMedPubMedCentralCrossRef
92.
Conrad K, Röber N, Andrade LE, Mahler M. The clinical relevance of anti-DFS70 autoantibodies. Clin Rev Allergy Immunol. 2017;52:202–16.PubMedCrossRef
93.
Mahler M, Meroni PL, Andrade LE, et al. Towards a better understanding of the clinical association of anti-DFS70 autoantibodies. Autoimmun Rev. 2016;15:198–201.PubMedCrossRef
94.
Dellavance A, Viana VS, Leon EP, et al. The clinical spectrum of antinuclear antibodies associated with the nuclear dense fine speckled immunofluorescence pattern. J Rheumatol. 2005;32:2144–9.PubMed
95.
Bizzaro N, Tonutti E, Tampoia M, et al. Specific chemoluminescence and immunoasdorption tests for anti-DFS70 antibodies avoid false positive results by indirect immunofluorescence. Clin Chim Acta. 2015;451:271–7.PubMedCrossRef
96.
Miyara M, Albesa R, Charuel JL, et al. Clinical phenotypes of patients with anti-DFS70/LEDGF antibodies in a routine ANA referral cohort. Clin Dev Immunol. 2013;2013:703759.PubMedPubMedCentralCrossRef
97.
Carter JB, Carter S, Saschenbrecker S, Goeckeritz BE. Recognition and relevance of anti-DFS70 autoantibodies in routine antinuclear autoantibodies testing at a community hospital. Front Med. 2018;5:88.CrossRef
98.
Carbone T, Pafundi V, Tramontano G, et al. Prevalence and serological profile of anti-DFS70 positive subjects from a routine ANA cohort. Sci Rep. 2019;9:2177.PubMedPubMedCentralCrossRef
99.
100.
Fitch-Rogalsky C, Steber W, Mahler M, et al. Clinical and serological features of patients referred through a rheumatology triage system because of positive antinuclear antibodies. PLoS ONE. 2014;9:e93812.PubMedPubMedCentralCrossRef
101.
Watanabe A, Kodera M, Sugiura K, et al. Anti-DFS70 antibodies in 597 healthy hospital workers. Arthritis Rheum. 2004;50:892–900.PubMedCrossRef
102.
Mahler M, Parker T, Peebles CL, et al. Anti-DFS70/LEDGF antibodies are more prevalent in healthy individuals compared to patients with systemic autoimmune rheumatic diseases. J Rheumatol. 2012;39:2104–10.PubMedCrossRef
103.
Mahler M, Hanly JG, Fritzler MJ. Importance of the dense fine speckled pattern on HEp-2 cells and anti-DFS70 antibodies for the diagnosis of systemic autoimmune diseases. Autoimmun Rev. 2012;11:642–5.PubMedCrossRef
104.
Mahler M, Fritzler MJ. The clinical significance of the dense fine speckled immunofluorescence pattern on HEp-2 cells for the diagnosis of systemic autoimmune diseases. Clin Dev Immunol. 2012;2012:494356.PubMedPubMedCentralCrossRef
105.
Seelig CA, Bauer O, Seelig HP. Autoantibodies against DFS70/LEDGF exclusion markers for systemic autoimmune rheumatic diseases (SARD). Clin Lab. 2016;62:499–517.PubMedCrossRef
106.
Shovman O, Gilburd B, Chayat C, et al. Prevalence of anti-DFS70 antibodies in patients with and without systemic autoimmune rheumatic diseases. Clin Exp Rheumatol. 2018;36:121–6.PubMed
107.
Jeong J, Kim DH, Park G, et al. Clinical significance of anti-dense fine speckled 70 antibody in patients with fibromyalgia. Korean J Intern Med. 2019;34:426–33.PubMedCrossRef
108.
Bonroy C, Schouwers S, Berth M, et al. The importance of detecting anti-DFS70 in routine clinical practice: comparison of different care settings. Clin Chem Lab Med. 2018;56:1090–9.PubMedCrossRef
109.
Albesa R, Sachs U, Infantino M, et al. Increased prevalence of anti-DFS70 antibodies in young females: experience from a large international multi-center study on blood donors. Clin Chem Lab Med. 2019;57:999–1005.PubMedCrossRef
110.
Nilsson AC, Voss A, Lillevang ST. DFS70 autoantibodies are rare in healthy Danish individuals but may still serve as a diagnostic aid. Scand J Immunol. 2015;82:547–8.PubMedCrossRef
111.
Muro Y, Sugiura K, Morita Y, Tomita Y. High concomitance of disease marker autoantibodies in anti-DFS70/LEDGF autoantibody-positive patients with autoimmune rheumatic disease. Lupus. 2008;17:171–6.PubMedCrossRef
112.
Mariz HA, Sato EI, Barbosa SH, et al. Pattern on the antinuclear antibody-HEp-2 test is a critical parameter for discriminating antinuclear antibody-positive healthy individuals and patients with autoimmune rheumatic diseases. Arthritis Rheum. 2011;63:191–200.PubMedCrossRef
113.
Infantino M, Pregnolato F, Bentow C, et al. Only monospecific anti-DFS70 antibodies aid in the exclusion of antinuclear antibody associated rheumatic diseases: an Italian experience. Clin Chem Lab Med. 2019;57:1764–9.PubMedCrossRef
114.
Lyu Y, Boerner E, Theegarten D, et al. Utility of anti-DSF70 antibodies to predict connective tissue disease in patients originally presenting with idiopathic interstitial pneumonia. Respiration. 2019;98:29–37.PubMedCrossRef
115.
Fabris M, Zago S, Tosolini R, et al. Anti-DFS70 antibodies: a useful biomarker in a pediatric case with suspected autoimmune disease. Pediatrics. 2014;134:e1706–8.PubMedCrossRef
116.
Bizzaro N, Tonutti E, Villalta D. Recognizing the dense fine speckled/lens epithelium-derived growth factor/p75 pattern on HEP-2 cells: not an easy task! Comment on the article by Mariz et al. Arthritis Rheum. 2011;63:4036–7.PubMedCrossRef
117.
Bentow C, Fritzler MJ, Mummert E, Mahler M. Recognition of the dense fine speckled (DFS) pattern remains challenging: results from an international internet-based survey. Autoimmun Highlights. 2016;7:8.CrossRef
118.
Peker BO, Şener AG, Tarhan EF, Kaya S. Investigation of anti-DFS70 antibody in patients with systemic autoimmune rheumatic diseases. Clin Rheumatol. 2019;38:3627–33.PubMedCrossRef
119.
Mutlu E, Eyigör M, Mutlu D, Gültekin M. Confirmation of anti-DFS70 antibodies is needed in routine clinical samples with DFS staining pattern. Cent Eur J Immunol. 2016;41:6–11.PubMedPubMedCentralCrossRef
120.
Bizzaro N, Pesente F, Cucchiaro F, et al. Anti-DFS70 antibodies detected by immunoblot methods: a reliable tool to confirm the dense fine speckles ANA pattern. J Immunol Methods. 2016;436:50–3.PubMedCrossRef
121.
Bentow C, Rosenblum R, Correia P, et al. Development and multi-center evaluation of a novel immunoadsorption method for anti-DFS70 antibodies. Lupus. 2016;25:897–904.PubMedCrossRef
122.
Infantino M, Shovman O, Pérez D, et al. A better definition of the anti-DFS70 antibody screening by IIF methods. J Immunol Methods. 2018;461:110–6.PubMedCrossRef
123.
Infantino M, Shovman O, Gilburd B, et al. Improved accuracy in DFS pattern interpretation using a novel HEp-2 ELITE system. Clin Rheumatol. 2019;38:1293–9.PubMedCrossRef
124.
Mahler M, Andrade LE, Casiano CA, et al. Anti-DFS70 antibodies: an update on our current understanding and their clinical usefulness. Expert Rev Clin Immunol. 2019;15:241–50.PubMedCrossRef
125.
Yamada K, Senju S, Shinohara T, et al. Humoral immune response directed against LEDGF in patients with VKH. Immunol Lett. 2001;78:161–8.PubMedCrossRef
126.
Dellavance A, Baldo DC, Zheng B, et al. Establishment of an international autoantibody reference standard for human anti-DFS70 antibodies: proof-of-concept study for a novel Megapool strategy by pooling individual specific sera. Clin Chem Lab Med. 2019;57:1754–63.PubMedCrossRef
127.
Choi MY, Clarke AE, St Pierre Y, et al. The prevalence and determinants of anti-DFS70 autoantibodies in an international inception cohort of systemic lupus erythematosus patients. Lupus. 2017;26:1051–9.PubMedCrossRef
128.
Gundín S, Irure-Ventura J, Asensio E, et al. Measurement of anti-DFS70 antibodies in patients with ANA-associated autoimmune rheumatic diseases suspicion is cost-effective. Autoimmun Highlights. 2016;7:10.CrossRef
129.
130.
Lucas S, Chang WL, Merien F. Prevalence and clinical significance of anti-DFS70 in antinuclear antibody (ANA)-positive patients undergoing routine ANA testing in a New Zealand public hospital. J Rheumatol. 2018;45:289–91.PubMedCrossRef
131.
Hissaria P, Broadfoot A, Baumgart KW. Revisiting the antinuclear antibody test with emphasis on a new pattern: anti-DFS70 antibody. Med J Aust. 2019;210:69–71.PubMedCrossRef
132.
Lee H, Kim Y, Han K, Oh EJ. Application of anti-DFS70 antibody and specific autoantibody test algorithms to patients with the dense fine speckled pattern on HEp-2 cells. Scand J Rheumatol. 2016;45:122–8.PubMedCrossRef
133.
Kang SY, Lee WI, Kim MH, La Jeon Y. Clinical use of anti-DFS70 autoantibodies. Rheumatol Int. 2019;39:1423–9.PubMedCrossRef
134.
La Jeon Y, Kang SY, Lee WI, Kim MH. Clinical aspects of the dense fine speckled pattern in indirect immunofluorescence-antinuclear antibody screening and its association with DFS70 autoantibodies. Ann Clin Lab Sci. 2019;49:496–502.PubMed
135.
Basu A, Woods-Burnham L, Ortiz G, et al. Specificity of antinuclear autoantibodies recognizing the dense fine speckled nuclear pattern: preferential targeting of DFS70/LEDGF over its interacting partner MeCP2. Clin Immunol. 2015;161:241–50.PubMedPubMedCentralCrossRef
136.
Vázquez-Del Mercado M, Gómez-Bañuelos E, Navarro-Hernández RE, et al. Detection of autoantibodies to DSF70/LEDGFp75 in Mexican Hispanics using multiple complementary assay platforms. Autoimmun Highlights. 2017;8:1.CrossRef
137.
Mahler M, Andrade LE, Casiano CA, et al. Implications for redefining the dense fine speckled and related indirect immunofluorescence patterns. Expert Rev Clin Immunol. 2019;15:447–8.PubMedCrossRef
138.
Dai L, Li J, Ortega R, Qian W, et al. Preferential autoimmune response in PCa to cyclin B1 in a panel of tumor-associated antigens. J Immunol Res. 2014;2014:827827.PubMedPubMedCentralCrossRef
139.
Xie C, Kim HJ, Haw JG, et al. A novel multiplex assay combining autoantibodies plus PSA has potential implications for classification of PCa from non-malignant cases. J Transl Med. 2011;9:43.PubMedPubMedCentralCrossRef
140.
O’Rourke DJ, DiJohnson DA, Caiazzo RJ Jr, et al. Autoantibody signatures as biomarkers to distinguish PCa from benign prostatic hyperplasia in patients with increased serum prostate specific antigen. Clin Chim Acta. 2012;413:561–7.PubMedCrossRef
141.
Bizzaro N, Tonutti E, Visentini D, et al. Antibodies to the lens and cornea in anti-DFS70-positive subjects. Ann N Y Acad Sci. 2007;1107:174–83.PubMedCrossRef
142.
Pérez D, Azoulay D. Anti-DFS70 antibodies in HIV-1-positive individuals. Curr Opin Rheumatol. 2018;30:361–4.PubMedCrossRef
143.
144.
Mahroum N, Perez D, Shovman O, et al. Anti-DFS70 among HIV-positive individuals—a prospective study. Best Pract Res Clin Rheumatol. 2018;32:605–9.PubMedCrossRef
145.
Bao L, Hannon C, Cruz-Mignoni A, et al. Intracellular immunization against HIV infection with an intracellular antibody that mimics HIV integrase binding to the cellular LEDGF protein. Sci Rep. 2017;7:16869.PubMedPubMedCentralCrossRef
146.
Wu C, Jain MR, Li Q, et al. Identification of novel nuclear targets of human thioredoxin 1. Mol Cell Proteom. 2014;13:3507–18.CrossRef
147.
Smallwood MJ, Nissim A, Knight AR, et al. Oxidative stress in autoimmune rheumatic diseases. Free Radic Biol Med. 2018;125:3–14.PubMedCrossRef
148.
Infantino M, Carbone T, Manfredi M, et al. Are anti-DFS70 autoantibodies protective? Isr Med Assoc J. 2019;21:509–11.PubMed
149.
Muro Y, Sugiura K, Nakashima R, et al. Low prevalence of anti-DFS70/LEDGF antibodies in patients with dermatomyositis and other systemic autoimmune rheumatic diseases. J Rheumatol. 2013;40:92–3.PubMedCrossRef
150.
Infantino M, Shovman O, Pérez D, et al. Anti-DFS70 autoantibodies in undifferentiated connective tissue diseases subjects: what’s on the horizon? Rheumatology. 2018;57:1293–8.PubMedCrossRef
151.
Ayaki M, Sueno T, Singh DP, et al. Antibodies to lens epithelium-derived growth factor (LEDGF) kill epithelial cells of whole lenses in organ culture. Exp Eye Res. 1999;69:139–42.PubMedCrossRef
152.
Ayaki M, Ohoguro N, Azuma N, et al. Detection of cytotoxic anti-LEDGF autoantibodies in atopic dermatitis. Autoimmunity. 2002;35:319–27.PubMedCrossRef
153.
Xu X, Powell DW, Lambring CJ, et al. Human MCS5A1 candidate breast cancer susceptibility gene FBXO10 is induced by cellular stress and correlated with lens epithelium-derived growth factor (LEDGF). Mol Carcinog. 2014;53:300–13.PubMedCrossRef
154.
Pradeepa MM, Grimes GR, Taylor GC, et al. Psip1/Ledgf p75 restrains Hox gene expression by recruiting both trithorax and polycomb group proteins. Nucleic Acids Res. 2014;42:9021–32.PubMedPubMedCentralCrossRef
155.
Guo R, Ma Y, Zhao M, Zhang W, et al. Polymorphism rs2395655 affects LEDGF/p75 binding activity and p21WAF1/CIP1 gene expression in esophageal squamous cell carcinoma. Cancer Med. 2019;8:2313–24.PubMedPubMedCentralCrossRef
156.
Lopez AP, Kugelman JR, Garcia-Rivera J, et al. The structure-specific recognition protein 1 associates with lens epithelium-derived growth factor proteins and modulates HIV-1 replication. J Mol Biol. 2016;428:2814–31.PubMedPubMedCentralCrossRef
Metadata
Title
Twenty years of research on the DFS70/LEDGF autoantibody-autoantigen system: many lessons learned but still many questions
Authors
Greisha L. Ortiz-Hernandez
Evelyn S. Sanchez-Hernandez
Carlos A. Casiano
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Autoimmunity Highlights / Issue 1/2020
Print ISSN: 2038-0305
Electronic ISSN: 2038-3274
DOI
https://doi.org/10.1186/s13317-020-0126-4

Other articles of this Issue 1/2020

Autoimmunity Highlights 1/2020 Go to the issue

Case Report

Castleman disease and SLE in a G6PD-deficient Marfan patient: a case report and literature review

Review

The search for the Holy Grail: autoantigenic targets in primary sclerosing cholangitis associated with disease phenotype and neoplasia

Original Research

A comprehensive analysis of antigen-specific autoimmune liver disease related autoantibodies in patients with multiple sclerosis

Original Research

Clinical comparisons between previously diagnosed SLE and newly diagnosed SLE by kidney biopsy

Editorial

The clinical and the laboratory autoimmunologist: Where do we stand?

Review

The perspective on standardisation and harmonisation: the viewpoint of the EASI president
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits